iNtRON Biotechnology, Inc. (048530.KQ)
KRW 5500.0
(-4.35%)
KRW 5500.0
(-4.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.23 Billion KRW | -3235.72% |
| 2022 | 13.21 Billion KRW | -99.61% |
| 2021 | 13.74 Billion KRW | -33.57% |
| 2020 | 19.8 Billion KRW | 542.36% |
| 2019 | 465.87 Million KRW | -193.42% |
| 2018 | 8.4 Billion KRW | 185.17% |
| 2017 | -8.04 Billion KRW | -9179.91% |
| 2016 | -2.04 Billion KRW | -98.3% |
| 2015 | 3.1 Billion KRW | 0.0% |
| 2012 | -56.58 Million KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -585.09 Million KRW | 86.22% |
| 2024 Q2 | -638.78 Million KRW | 513.71% |
| 2023 FY | - KRW | -3235.72% |
| 2023 Q3 | -249.26 Million KRW | 59.98% |
| 2023 Q4 | 369.57 Million KRW | 248.26% |
| 2023 Q2 | -622.86 Million KRW | 32.34% |
| 2023 Q1 | -920.62 Million KRW | -31.26% |
| 2022 Q3 | -79.83 Million KRW | 93.03% |
| 2022 FY | - KRW | -99.61% |
| 2022 Q4 | -701.37 Million KRW | -778.54% |
| 2022 Q2 | -1.14 Billion KRW | -158.14% |
| 2022 Q1 | 1.97 Billion KRW | -54.38% |
| 2021 Q1 | 1.89 Billion KRW | -59.0% |
| 2021 FY | - KRW | -33.57% |
| 2021 Q4 | 4.32 Billion KRW | 96.76% |
| 2021 Q2 | 2.86 Billion KRW | 51.41% |
| 2021 Q3 | 2.19 Billion KRW | -23.39% |
| 2020 Q3 | 1.18 Billion KRW | -90.19% |
| 2020 FY | - KRW | 542.36% |
| 2020 Q4 | 4.61 Billion KRW | 291.0% |
| 2020 Q1 | -533.48 Million KRW | 34.0% |
| 2020 Q2 | 12.04 Billion KRW | 2356.99% |
| 2019 FY | - KRW | -193.42% |
| 2019 Q4 | -808.31 Million KRW | 13.26% |
| 2019 Q3 | -931.93 Million KRW | -115.7% |
| 2019 Q2 | -432.05 Million KRW | 44.05% |
| 2019 Q1 | -772.2 Million KRW | -108.24% |
| 2018 FY | - KRW | 185.17% |
| 2018 Q2 | -699.89 Million KRW | 23.0% |
| 2018 Q1 | -908.89 Million KRW | 4.39% |
| 2018 Q3 | -1.65 Billion KRW | -136.51% |
| 2018 Q4 | 9.37 Billion KRW | 666.08% |
| 2017 Q1 | -594.62 Million KRW | 74.99% |
| 2017 FY | - KRW | -9179.91% |
| 2017 Q4 | -950.6 Million KRW | 7.6% |
| 2017 Q3 | -1.02 Billion KRW | -139.11% |
| 2017 Q2 | -430.23 Million KRW | 27.65% |
| 2016 FY | - KRW | -98.3% |
| 2016 Q4 | -2.37 Billion KRW | -1849.33% |
| 2016 Q3 | -121.96 Million KRW | -188.28% |
| 2016 Q2 | 138.14 Million KRW | 9.68% |
| 2016 Q1 | 125.94 Million KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2013 Q3 | 261.47 Million KRW | -2.67% |
| 2013 Q2 | 268.65 Million KRW | -39.91% |
| 2013 Q1 | 447.08 Million KRW | 467.22% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | -121.74 Million KRW | -396.46% |
| 2012 Q3 | 41.06 Million KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 96.381% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 157.346% |
| Bioneer Corporation | 10.04 Billion KRW | 162.078% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | -1324.008% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 67.849% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 85.432% |
| Helixmith Co., Ltd | -53 Billion KRW | 88.237% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 108.895% |
| Medy-Tox Inc. | 32.69 Billion KRW | 119.067% |
| Peptron, Inc. | -12.65 Billion KRW | 50.716% |
| Amicogen, Inc. | 13.95 Billion KRW | 144.683% |
| Genexine, Inc. | -40.87 Billion KRW | 84.748% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 175.759% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 91.266% |
| ALTEOGEN Inc. | 440.04 Million KRW | 1516.833% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 105.98% |
| SillaJen, Inc. | -17.35 Billion KRW | 64.071% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 156.639% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | 44.009% |
| Genomictree Inc. | -6.33 Billion KRW | 1.535% |
| MedPacto, Inc. | -32.6 Billion KRW | 80.88% |
| D&D Pharmatech | -9.05 Billion KRW | 31.169% |
| EASY BIO,Inc. | 24.32 Billion KRW | 125.633% |
| GI Innovation, Inc. | -51.33 Billion KRW | 87.854% |